Jan. 28, 2025 – hydrochlorothiazide (Inzirqo) 505(b)(2) NDA approval; Standard Review; first oral suspension formulation of hydrochlorothiazide; previously available oral solutions are no longer...

Proposed indications Hematological malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndromes (MDS). FDA approval timeline April 6, 2026...

May 1, 2024 Obesity is a global epidemic and major public health issue that has grown in prevalence over recent decades in adults, adolescents and children. This Clinical Insights white paper...

Proposed indications Non-muscle invasive bladder cancer (NMIBC) FDA approval timeline March to May 2026 Standard Review Place in therapy Sasanlimab is a humanized immunoglobulin G4 (IgG4)...

publications High-Cost Therapy Profile: April 2025 Deramiocel Intravenous (IV) | Nippon Shinyaku Co., Ltd./Capricor Therapeutics, Inc. Clinical deep dive Disease state overview DMD is a severe,...

January 31, 2025 All brand names are property of their respective owners. Dec. 13, 2024 – cosibelimab-ipdl (Unloxcyt) Checkpoint’s Unloxcyt has received FDA approval for the treatment of adults...

A roundup of Prime's award-winning presentations and insights at AMCP Nexus in Las Vegas.

The Spring 2026 Prime Therapeutics Report delivers a forward-looking view of specialty and rare disease management—highlighting breakthrough approvals, expanding pipelines and the payer strategies...

13th annual report the preeminent source for medical benefit drug trend

Managed Healthcare Executive

Nov. 29, 2024 - ustekinumab-kfce (Yesintek) The FDA has approved Biocon’s Yesintek as a biosimilar to ustekinumab (Stelara). This human interleukin (IL)-12 and IL-23 antagonist is indicated for all...

More than 300 pharma representatives attended this annual gathering to learn more about what Prime/MRx has to offer

Reimagine your pharmacy benefit partner Get expert insights Go Somewhere Save, Simplify, Support™ Biologic drugs are transforming lives for the better, yet often at a substantial cost. Biosimilars,...

research 10 research posters presented by Prime at AMCP Nexus 2024 Studies include Prime’s GLP-1 obesity research, health equity, and real world case studies Evaluating the 10-Year Impact of an...

Care Specialists program Help your members on high-cost clinical drugs Insert Link Help members and their prescribers make better decisions about medicines through this clinical intelligence hub...

Biobetters are just a nickname; they’re based on existing biologics but with a few key differences

Weight loss Support and empower weight loss in a healthy, manageable and sustainable way with customized paths for each member. Medication management Improve drug adherence or reduce the number of...

Oncology Insights Oncology Case Management and Navigation: How do they differ? Caring for and treating a patient with cancer is complex. Many patients struggle to coordinate therapy, manage...

*select countries included adolescents 12 years and older weighing 30 kg or more Autoimmune/immunology Proposed indications Treatment of Steroid-Refractory Acute Graft vs. Host Disease (SR-aGVHD) –...

Flexible, cost-effective, strategic partnership Specialty drugs have changed the pharmacy landscape over the past decade and now represent more than half of total drug spend. Having a strong...

50M Footnotes As many as 50M people in the United States have an autoimmune disease, making it the third most prevalent disease category, surpassed only by cancer and heart disease.2 Unlock...

High Cost Therapy Profile Eyebrow High-Cost Therapy Profile: February Detailed information about Marnetegragene autotemcel Intravenous (IV) Gene Therapy/Immunology Marnetegragene autotemcel...

For the first time, Prime Therapeutics hosted the AMCP Nexus specialty keynote, addressing trends in cell and gene therapy and rare disease and immunology categories

Insert Link Medical Formulary Strategy ensures the most appropriate and clinically effective medical benefit drugs are evaluated with product-preferencing strategies, for all lines of business....

Medication Nonadherence Social Determinants of Health Risk Score: Development and Use 2024 AMCP Annual Posters Real-World First Year Cost-Effectiveness Assessment of Glucagon-Like Peptide-1...

Clinical deep dive Disease state overview WAS is a rare, X-linked, genetic disorder characterized by thrombocytopenia, eczema, immunodeficiency, and increased risk of autoimmunity and...

All brand names are property of their respective owners. References Kim SY, Park HS, Chiang AC. Small Cell Lung Cancer: A Review. JAMA. 2025;333(21):1906-1917. doi:10.1001/jama.2025.0560...

Last year, Oncology Insights brought you the most talked about topics in 2024. As we enter this new year, let us review these impactful and potentially practicing changing subjects that are likely...

Marquee event showcased new Prime, our energy, ambition and transformative journey

May 22, 2025 – mepolizumab (Nucala) GlaxoSmithKline; an IL-5 antagonist monoclonal antibody New indication: add-on maintenance treatment of adults with inadequately controlled chronic obstructive...

Methodological Framework for Propensity Adjusted Benchmarks for Pharmacy Key Performance Indicators The purpose of the study was to create a methodological framework for using propensity score...

Drs. Tracey Garcia and Amy Pappas, board-certified neurologists, reviewed migraine risk factors and treatments in a recent webinar moderated by Dr. Marci Chodroff, vice president of medical affairs

Prime is pleased to present the seventh edition of the Employer Market Insights Report. Within this one-of-a-kind publication, you’ll find critical pharmacy trend insights that will help you make...

Clinical deep dive Disease state overview Myelodysplastic syndromes (MDS) are classified as disorders in which there are abnormal (dysplastic) hematopoietic stem cells in the bone marrow, leading...

Empowering client, providers and members 2024: Using real-time pricing, Pharmacy Match drives affordability for plan sponsors while offering access to the most competitive pharmacy for each member....

Event features discussions about health care industry trends, best practices and innovations

Jessica Johnson, clinical consultant at Prime Therapeutics, shares how the Special Investigations Unit (SIU) helps prevent fraud, waste and abuse (FWA) in health care

Whitepaper Tab 1 Myth 1 Myth 2 Myth 3 Myth 4 Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed nec ornare mi. Praesent ultrices ipsum eget est rutrum, eget congue orci molestie. Sed diam...

Home Our solutions Modern technology MyRxInsights Our advanced analytics platform helps boost your clinical impact and drive down costs by delivering descriptive, diagnostic, predictive and...

Clinical deep dive Disease state overview MacTel type 2 is a rare neurodegenerative disease that affects the macula, which processes central and color vision. It is a bilateral asymmetric...